Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Urovant gains global rights to ICI's gene therapy for OAB

Executive Summary

Roivant Sciences GMBH's Urovant Sciences Ltd. licensed exclusive worldwide development, manufacturing, and commercialization rights to Ion Channel Innovations LLC's naked DNA gene therapy hMaxi-K, for overactive bladder (OAB).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register